# Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers

> **NCT01434680** · PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 992 (actual)

## Conditions studied

- Meningococcal Disease
- Meningococcal Meningitis

## Interventions

- **BIOLOGICAL:** MenC-CRM LIQ
- **BIOLOGICAL:** MenC-CRM ROS
- **BIOLOGICAL:** MenC-CRM EMV

## Key facts

- **NCT ID:** NCT01434680
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 992 (ACTUAL)
- **Last updated:** 2017-04-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01434680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01434680, "Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01434680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*